Mika closes oversubscribed Series A financing round!
We are pleased to announce that our portfolio company Mika has closed a Series A financing round of over €10 million.
The Series A was led by new investor Debiopharm and completed by co-investors Ship2B Ventures, IBB Ventures, Ananda Impact Ventures and us. The fresh capital gives Mika the opportunity to accelerate its international expansion.
Mika is a personalized therapy support in oncology for all types of cancer.The app was developed by the digital health company Fosanis in cooperation with leading oncology research institutions and tumor centers such as Berliner Charité and Uniklinikum Leipzig. In addition to imparting knowledge, it accompanies patients during their illness with scientifically proven methods and validated therapy management techniques. The program includes exercise training, nutritional recommendations and mindfulness exercises.
Andrea Buhofer, Partner at EquityPitcher Ventures, focuses on the growing relevance of patient-centric solutions in integrative digital oncology:
“Personalized digital and easily accessible support in cancer therapy is becoming increasingly important. Mika is an extremely user-friendly app, and we are very happy to help Mika evolve and bring digital cancer therapy to more patients.”
Mika will use the new capital for international expansion. Mika is expected to become available in the UK before the end of this year. In addition, collaborations with renowned international cancer research centers are being sought for further studies on the effectiveness of AI-based personalization in digital interventions.
Dr. Gandolf Finke, Mika founder and CEO of Fosanis GmbH, said:
"Digital health applications and especially Digital Therapeutics are becoming increasingly important worldwide. Our current financing round is an important milestone in our company's history. It enables us to position Mika internationally. We welcome the new investors on board and look forward to adding new chapters to Mika's success story together with them."
Click here for the full press release.